Literature DB >> 17594394

Executive functioning in children and adolescents with phenylketonuria.

K H VanZutphen1, W Packman, L Sporri, M C Needham, C Morgan, K Weisiger, S Packman.   

Abstract

This study addresses the effects of dietary adherence, phenylalanine (phe) levels, and age on performance of executive functioning (EF) tasks in children and adolescents with phenylketonuria (PKU). We herein collate formerly discrete findings to understand the relationship among actual clinical parameters and EF in PKU. Fifteen subjects (age range 8-20 years) with PKU were compared with the normative sample on the Delis-Kaplan EF Battery and on the Wechsler Abbreviated Scales of Intelligence to examine the relationship between EF skills, phe levels, age, and dietary adherence. At the time of the assessment, the mean age of participants was 14.8 years, mean lifetime phe levels ranged from 216 to 1200 microM (mean 594 microM); and concurrent phe levels ranged from 222 to 1730 microM (mean 660 microM). Children and adolescents with PKU showed lower performance in several EF skills: initiation of problem solving, concept formation, and reasoning. Performance on EF tasks requiring inhibitory control, cognitive flexibility and set shifting decreased at higher phe levels. Phe levels were positively correlated to age and inversely related to dietary adherence. We conclude that dynamic clinical parameters appear to govern EF in patients with PKU. We suggest that when adolescents decrease dietary compliance, changes in EF skills occur. Therefore, there is a need to specifically monitor EF skills in patients with PKU during the transition to, and during, adolescence.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17594394     DOI: 10.1111/j.1399-0004.2007.00816.x

Source DB:  PubMed          Journal:  Clin Genet        ISSN: 0009-9163            Impact factor:   4.438


  19 in total

1.  A randomized, placebo-controlled, double-blind trial of supplemental docosahexaenoic acid on cognitive processing speed and executive function in females of reproductive age with phenylketonuria: A pilot study.

Authors:  S H L Yi; J A Kable; M L Evatt; R H Singh
Journal:  Prostaglandins Leukot Essent Fatty Acids       Date:  2011-10-14       Impact factor: 4.006

2.  Demographic and Psychosocial Influences on Treatment Adherence for Children and Adolescents with PKU: A Systematic Review.

Authors:  Emma Medford; Dougal Julian Hare; Anja Wittkowski
Journal:  JIMD Rep       Date:  2017-08-25

3.  Developmental Trajectories of Executive and Verbal Processes in Children with Phenylketonuria.

Authors:  Zoë W Hawks; Michael J Strube; Neco X Johnson; Dorothy K Grange; Desirée A White
Journal:  Dev Neuropsychol       Date:  2018-02-12       Impact factor: 2.253

4.  Health-related quality of life in children and adolescents with phenylketonuria: unimpaired HRQoL in patients but feared school failure in parents.

Authors:  Eva Thimm; Lisa Elena Schmidt; Katrin Heldt; Ute Spiekerkoetter
Journal:  J Inherit Metab Dis       Date:  2013-01-08       Impact factor: 4.982

5.  Pharmacologic inhibition of L-tyrosine degradation ameliorates cerebral dopamine deficiency in murine phenylketonuria (PKU).

Authors:  Cary O Harding; Shelley R Winn; K Michael Gibson; Erland Arning; Teodoro Bottiglieri; Markus Grompe
Journal:  J Inherit Metab Dis       Date:  2014-02-03       Impact factor: 4.982

6.  Correlation of age-specific phenylalanine levels with intellectual outcome in patients with phenylketonuria.

Authors:  Krista S Viau; Heidi J Wengreen; Sharon L Ernst; Nancy L Cantor; Larissa V Furtado; Nicola Longo
Journal:  J Inherit Metab Dis       Date:  2011-05-10       Impact factor: 4.982

7.  Executive strategic processing during verbal fluency performance in children with phenylketonuria.

Authors:  Pia Banerjee; Dorothy K Grange; Robert D Steiner; Desirée A White
Journal:  Child Neuropsychol       Date:  2010-12-07       Impact factor: 2.500

8.  High dose sapropterin dihydrochloride therapy improves monoamine neurotransmitter turnover in murine phenylketonuria (PKU).

Authors:  Shelley R Winn; Tanja Scherer; Beat Thöny; Cary O Harding
Journal:  Mol Genet Metab       Date:  2015-11-26       Impact factor: 4.797

9.  Psychosocial issues in families affected by maple syrup urine disease.

Authors:  Wendy Packman; Shelly L Henderson; Indira Mehta; Rama Ronen; Dean Danner; Beth Chesterman; Seymour Packman
Journal:  J Genet Couns       Date:  2007-08-17       Impact factor: 2.537

10.  Blood phenylalanine reduction corrects CNS dopamine and serotonin deficiencies and partially improves behavioral performance in adult phenylketonuric mice.

Authors:  Shelley R Winn; Tanja Scherer; Beat Thöny; Ming Ying; Aurora Martinez; Sydney Weber; Jacob Raber; Cary O Harding
Journal:  Mol Genet Metab       Date:  2017-10-19       Impact factor: 4.797

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.